13 Results for "

vascular complications

" in MedChemExpress (MCE) Product Catalog:
Products (13)

13 Results for "vascular complications" in MCE Product Catalog:

21
21 Cited Publications
Cat. No.: HY-N1362
CAS No.: 121521-90-2
Synonyms: Lithospermic acid B
Salvianolic acid B is an active ingredient of Salvia miltiorrhiza, which has been widely applied in China for the management of various microcirculation-related disorders, such as cardiovascular disease, cerebrovascular disease, and diabetic vascular complication.
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-10930
CAS No.: 1238673-32-9
Purity:  99.91%
Research Areas:  

Cancer

UNC0321 is a potent and selective histone methyltransferase G9a inhibitor with a Ki of 63 pM and with assay-dependent IC50 values of 6-9 nM. UNC0321 also inhibits GLP with assay-dependent IC50 values of 15-23 nM. UNC0321 has anti-apoptotic activity and has potential application in diabetic vascular complications .
loading...
    loading...
Cat. No.: HY-109106A
CAS No.: 2052969-18-1
Purity:  99.91%
Synonyms: SK-1403; AJT240; PLS240
Target:  

CaSR

Research Areas:  

Endocrinology

Upacicalcet sodium is a non-peptide calcimimetic that acts as a CaSR agonist (EC50 = 10.8 nM). Upacicalcet sodium reduces serum intact parathyroid hormone (iPTH) and serum Ca 2+ levels, reducing hypocalcemia and gastrointestinal complications. Upacicalcet sodium sodium improves vascular calcification and bone disorders in the Adenine (HY-B0152)-induced secondary hyperparathyroidism (SHPT) rat model. Upacicalcet sodium sodium inhibits cortical pore formation and reduces bone fibrosis in rats with chronic kidney disease (CKD). Upacicalcet sodium is useful for studying SHPT .
loading...
    loading...
Cat. No.: HY-W100287
CAS No.: 4532-33-6
Murrayafoline A is a carbazole alkaloid that can be extracted from Murraya tetramera. Murrayafoline A directly targets Specificity protein 1 (Sp1), thereby inhibiting NF-κB and MAPK signaling pathways. Murrayafoline a induces a G0/G1-phase arrest in platelet-derived growth factor (PDGF)-stimulated vascular smooth muscle cells. Murrayafoline A attenuates the Wnt/β-catenin pathway by promoting the degradation of intracellular β-catenin proteins. Murrayafoline A enhances the contraction of rat ventricular myocytes and L-type calcium current by activating protein kinase C. Murrayafoline A inhibits LPS (HY-D1056)-induced neuroinflammation in vivo. Murrayafoline A can be used for the study of inflammation, vascular complications and colon cancer .
loading...
    loading...
Cat. No.: HY-P1615
CAS No.: 1006388-38-0
Synonyms: UPARANT
Cenupatide (UPARANT) is a uPAR and FPR antagonist with anti-angiogenic, anti-inflammatory, and vascular barrier regulatory activities, as well as high stability and resistance to enzymatic degradation in blood/plasma. Cenupatide blocks the uPAR-FPR interaction, reduces VEGF-induced phosphorylation levels of AKT, VEGFR-2, STAT3, JNK, p38 MAPK, ERK1/2, and NF-κB p65, and inhibits αvβ3 integrin activation. Cenupatide suppresses endothelial cell migration, invasion, tube formation, and angiogenic signaling pathways, restores tight junctions and blood-retinal barrier integrity, reduces pro-inflammatory marker levels, and inhibits apoptosis. Cenupatide reduces retinal neovascularization, renal fibrosis, and vascular leakage, and restores visual function in preclinical models. Cenupatide is applicable to research related to retinopathy, diabetic complications, ocular diseases, cancer, and inflammatory diseases .
loading...
    loading...
Cat. No.: HY-N1362R
CAS No.: 121521-90-2
Synonyms: Lithospermic acid B (Standard)
Salvianolic acid B (Standard) is the analytical standard of Salvianolic acid B. This product is intended for research and analytical applications. Salvianolic acid B is an active ingredient of Salvia miltiorrhiza, which has been widely applied in China for the management of various microcirculation-related disorders, such as cardiovascular disease, cerebrovascular disease, and diabetic vascular complication.
loading...
    loading...
Cat. No.: HY-10383
CAS No.: 198279-45-7
J-104132 (L-753037) is a potent, orally active, selective and competitive ETA/ETB receptor antagonist with Ki of 0.034 nM for ETA and 0.104 nM for ETB receptors. J-104132 inhibits Endothelin-1 (ET-1) (HY-P71446)-induced signaling and vascular contractions in vitro. J-104132 alleviates hypertension, vascular remodeling, and diabetic endothelial dysfunction in vivo by dual ETA/ETB blockade. J-104132 can be used for research on diabetic vascular complications [1][3].
loading...
    loading...
Cat. No.: HY-109106
CAS No.: 1333218-50-0
Synonyms: SK-1403 free acid; AJT240 free acid; PLS240 free acid
Target:  

CaSR

Research Areas:  

Endocrinology

Upacicalcet is a non-peptide calcimimetic that acts as a CaSR agonist (EC50 = 10.8 nM). Upacicalcet reduces serum intact parathyroid hormone (iPTH) and serum Ca2+ levels, reducing hypocalcemia and gastrointestinal complications. Upacicalcet improves vascular calcification and bone disorders in the Adenine (HY-B0152)-induced secondary hyperparathyroidism (SHPT) rat model. Upacicalcet inhibits cortical pore formation and reduces bone fibrosis in rats with chronic kidney disease (CKD). Upacicalcet is useful for studying SHPT .
loading...
    loading...
Cat. No.: HY-109106B
CAS No.: 2649575-19-7
Purity:  ≥95.0%
Synonyms: (Rac)-SK-1403 free acid; (Rac)-AJT240 free acid; (Rac)-PLS240 free acid
Target:  

CaSR

Research Areas:  

Endocrinology

(Rac)-Upacicalcet is the racemate of Upacicalcet (HY-109106). Upacicalcet is a non-peptide calcimimetic that acts as a CaSR agonist (EC50 = 10.8 nM). Upacicalcet reduces serum intact parathyroid hormone (iPTH) and serum Ca2+ levels, reducing hypocalcemia and gastrointestinal complications. Upacicalcet improves vascular calcification and bone disorders in the Adenine (HY-B0152)-induced secondary hyperparathyroidism (SHPT) rat model. Upacicalcet inhibits cortical pore formation and reduces bone fibrosis in rats with chronic kidney disease (CKD). Upacicalcet is useful for studying SHPT .
loading...
    loading...
Cat. No.: HY-W100287R
CAS No.: 4532-33-6
Murrayafoline A (Standard) is the analytical standard of Murrayafoline A (HY-W100287). This product is intended for research and analytical applications. Murrayafoline A is a carbazole alkaloid that can be extracted from Murraya tetramera. Murrayafoline A directly targets Specificity protein 1 (Sp1), thereby inhibiting NF-κB and MAPK signaling pathways. Murrayafoline a induces a G0/G1-phase arrest in platelet-derived growth factor (PDGF)-stimulated vascular smooth muscle cells. Murrayafoline A attenuates the Wnt/β-catenin pathway by promoting the degradation of intracellular β-catenin proteins. Murrayafoline A enhances the contraction of rat ventricular myocytes and L-type calcium current by activating protein kinase C. Murrayafoline A inhibits LPS (HY-D1056)-induced neuroinflammation in vivo. Murrayafoline A can be used for the study of inflammation, vascular complications and colon cancer .
loading...
    loading...
Cat. No.: HY-10930R
CAS No.: 1238673-32-9
UNC0321 (Standard) is the analytical standard of UNC0321 (HY-10930). This product is intended for research and analytical applications. UNC0321 is a potent and selective histone methyltransferase G9a inhibitor with a Ki of 63 pM and with assay-dependent IC50 values of 6-9 nM. UNC0321 also inhibits GLP with assay-dependent IC50 values of 15-23 nM. UNC0321 has anti-apoptotic activity and has potential application in diabetic vascular complications .
loading...
    loading...
Cat. No.: HY-128613
CAS No.: 2423919-77-9
Synonyms: TZ-md
Terazosin-md (compound TZ-md), a derivative of both Alfuzosin (HY-B0192) and Terazosin (HY-B0371), is an orally active α1-adrenergic receptor antagonist. Terazosin-md has the functions of improving mitochondrial metabolism, degrading various pathological protein accumulations and improving the function of vascular endothelial cells. Terazosin-md shows effect in a mouse model with Alzheimer's disease. Terazosin-md can be used for research in Alzheimer's disease and related complications, and diseases associated with protein accumulation and metabolic disorders .
loading...
    loading...
Cat. No.: HY-109106AR
CAS No.: 2052969-18-1
Synonyms: SK-1403 (Standard); AJT240 (Standard); PLS240 (Standard)
Research Areas:  

Endocrinology

Upacicalcet sodium (Standard) is the analytical standard of Upacicalcet (sodium) (HY-109106A). This product is intended for research and analytical applications. Upacicalcet sodium is a non-peptide calcimimetic that acts as a CaSR agonist (EC50 = 10.8 nM). Upacicalcet sodium reduces serum intact parathyroid hormone (iPTH) and serum Ca2+ levels, reducing hypocalcemia and gastrointestinal complications. Upacicalcet sodium sodium improves vascular calcification and bone disorders in the Adenine (HY-B0152)-induced secondary hyperparathyroidism (SHPT) rat model. Upacicalcet sodium sodium inhibits cortical pore formation and reduces bone fibrosis in rats with chronic Kidney disease (CKd). Upacicalcet sodium is useful for studying SHPT .
loading...
    loading...
  • 1